- Alemtuzumab is given by intravenous infusion over 2 hours. The dose should be gradually increased to the recommended dose of 30 mg/day three times per week for 12 weeks.
- Medications that should be given during alemtuzumab therapy to prevent side effects and infections include oral antihistamines, acetaminophen (Tylenol), trimethoprim/sulfamethoxazole DS (Bactrim DS), and famciclovir (Famvir).
DRUG CLASS AND MECHANISM:
- Alemtuzumab is an injectable drug used for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). People with CLL have too many of a type of white blood cell called lymphocytes in the blood and bone marrow. Alemtuzumab is an antibody that targets a protein called CD52 that is found on the surface of the lymphocytes. Alemtuzumab attaches to lymphocytes and then activates the immune system to help kill the lymphocytes.
- The FDA approved alemtuzumab in May, 2001.
REFERENCE: FDA Prescribing Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.